Loading…

Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment

Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly act...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology 2010-07, Vol.161 (1), p.134-141
Main Authors: Barbai, V.H, Ujhelyi, E, Szlávik, J, Vietorisz, I, Varga, L, Fey, E, Füst, G, Bánhegyi, D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4⁺ cell count (
ISSN:0009-9104
1365-2249
DOI:10.1111/j.1365-2249.2010.04145.x